Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide in patients undergoing CABG for improved glucose control and hemodynamic values
2010-023839-42Phase 3Completed
- Sponsor
- General University Hospital in Prague
- Start
- Jan 2011
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3 trial of exenatide in type 2 diabetes mellitus (T2DM), coronary arteriosclerosis and left ventricular systolic dysfunction (LVSD), sponsored by General University Hospital in Prague. Primary endpoint: Perioperative echocardiographic parameters. Started Jan 2011; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)coronary arteriosclerosisleft ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on 2010-023839-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023839-42.